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Abstract
Background: Chronic active antibody-mediated rejection (c-aABMR) is an important cause of allograft failure and
graft loss in long-term kidney transplants.
Methods: To determine the efficacy and safety of combined therapy with rituximab, plasma exchange (PE) and
intravenous immunoglobulins (IVIG), a cohort of patients with transplant glomerulopathy (TG) that met criteria of
active cABMR, according to BANFF’17 classification, was identified.
Results: We identified 62 patients with active c-aABMR and TG (cg≥ 1). Twenty-three patients were treated with the
combination therapy and, 39 patients did not receive treatment and were considered the control group. There were no
significant differences in the graft survival between the two groups. The number of graft losses at 12 and 24 months and
the decline of eGFR were not different and independent of the treatment. A decrease of eGFR≥13 ml/min between
6 months before and c-aABMR diagnosis, was an independent risk factor for graft loss at 24 months (OR = 5; P = 0.01).
Infections that required hospitalization during the first year after c-aABMR diagnosis were significantly more frequent in
treated patients (OR = 4.22; P = 0.013), with a ratio infection/patient-year of 0.65 and 0.20 respectively.
Conclusions: Treatment with rituximab, PE, and IVIG in kidney transplants with c-aABMR did not improve graft survival
and was associated with a significant increase in severe infectious complications.
Trial registration: Agencia Española de Medicametos y Productos Sanitarios (AEMPS): 14566/RG 24161. Study code: UTR-
INM-2017-01.
Keywords: Kidney transplantation, Transplant glomerulopathy, Chronic active antibody-mediated rejection,
Rituximab, Infections
Background
Chronic active antibody-mediated rejection (c-aABMR) is
a major cause of renal allograft failure in kidney trans-
plants [1, 2]. Transplant glomerulopathy (TG), one of the
histological features of c-aABMR, results from continuous
endothelial injury and repair processes, leading to patho-
logical multi-layering of the glomerular basement mem-
brane [3]. The prevalence of TG increases over time after
transplantation and has been associated with reduced allo-
graft outcomes, with a mean allograft survival of 2 years
after diagnosis [2, 4–6].
Despite its clinical significance the available evidence
on treatment of c-aABMR with TG is scarce. Similar to
the treatment of active antibody-mediated rejection,
many centers use combinations of plasma exchange
(PE), immunoglobulin (IVIG) and rituximab (RTX)
* Correspondence: jrovira1@clinic.cat; fdiekman@clinic.cat
†Jordi Rovira and Fritz Diekmann contributed equally to this work.
2Laboratori Experimental de Nefrologia i Trasplantament (LENIT), IDIBAPS,
Barcelona, Spain
1Department of Nephrology and Renal Transplantation, ICNU, Hospital Clinic,
Barcelona, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Piñeiro et al. BMC Nephrology  (2018) 19:261 
https://doi.org/10.1186/s12882-018-1057-4
therapy for c-aABMR. Small and retrospective series of
cases reported a slight improvement in patients with
c-aABMR under IVIG and rituximab treatment [7–10].
In contrast, in two recent patients series, improve-
ments of graft survival were not observed when com-
paring untreated with treated patients, whereas
treated patients suffered a higher incidence of compli-
cations and adverse effects [11, 12]. However,
untreated groups were small in both studies.
Recently in a randomized trial, the efficacy of rituximab
and IVIG vs. placebo was tested in 24 patients with TG and
DSA. There was no difference in eGFR decline. Unfortu-
nately the study was underpowered, because the recruit-
ment was stopped early due to low inclusion rate [13].
In the present study, we retrospectively reviewed 62
patients with c-aABMR and TG to determine the effi-




We retrospectively reviewed our pathology database
between 2006 and 2015, identified all patients with TG
(cg ≥ 1 in the Banff histopathological classification) and
re-evaluated them according to Banff 2017 classification
criteria [3].
The inclusion criteria were the coexistence of c-aABMR
TG with microvascular injury (MVI) ≥2 (g + ptc ≥ 2), with
positive or negative C4d staining in peritubular capillaries
and positive donor-specific antibodies (DSA). The patients
with compatible histology, but negative DSA were in-
cluded in the analysis as suspicious of c-aABMR. Also, TG
plus positive C4d or TG with MVI =1 plus positive DSA
were included. The presence of concomitant cellular rejec-
tion required at least g of 1.
The decisions to perform a renal biopsy and patient
treatment were based on the clinical judgment at
c-aABMR diagnosis.
Every patient who received treatment with RTX, IVIG,
and PE after diagnosis of c-aABMR was included in the
treatment group. Patients who did not receive RTX,
IVIG neither PE, alone or in combination, were included
in the control group.
PE was performed in Cobe Spectra or Spectra Optia
separators (Terumo BCT, Lakewood, CO, USA) using
5% albumin (Albutein® 5%, Grífols, Spain) as a replace-
ment solution. One plasma volume was exchanged in
each session as previously reported [14].
The primary endpoint was graft survival. Secondary
endpoints were the evolution of glomerular filtration
rate and complications related to treatment.
The Institutional Ethics Committee approved the
study. The registration number was 14,566/RG 24161
(Agencia Española del Medicamento y Producto
Sanitario, AEMPS).
Clinical data
The clinical characteristics, immunosuppression, and
treatment were analyzed at the time of c-aABMR
diagnosis and in the follow-up period. We assessed
Charlson comorbidity index (CCI) at diagnosis of
c-aABMR [15]. In accordance with other groups, CCI
was unadjusted for age, and the minimum score of our
patients was 0 (2 points for renal insufficiency were not
added) [16–19].
We assessed renal function and proteinuria at
c-aABMR diagnosis, 6 months before and 6, 12,
24 months after diagnosis and at the end of follow-up.
Renal function was determined by serum creatinine and
by estimated glomerular filtration rate (eGFR) using the
Modification of Diet in Renal Disease (MDRD) formula
[20]. Proteinuria was evaluated using the proteinuria/
creatinine index [21].
Serum samples obtained at the moment of transplant-
ation and rejection were screened for HLA class I and II
antibodies using the Lifecodes LifeScreen Deluxe flow
bead assay (Immucor, Stamford, CT, USA). Antibody
specificities were determined using the Lifecodes Single
Antigen bead assay (Immucor, Stamford, CT, USA) in
patients with positive HLA antibodies.
Infections that required hospitalization at least 48 h
during the first year after c-aABMR diagnosis were ana-
lyzed. All immediate adverse events (AE), after IVIG, PE
and RTX infusion were registered.
Statistical analysis
Data were described as mean with standard deviation
(SD) or standard error of the mean (SEM), in case of
graphical presentation for quantitative variables and as
absolute and relative (%) frequencies for qualitative
variables. Group comparisons between patients with
or without the intake of rituximab were made by
Fisher’s exact, t-test or Mann Whitney U test for
independent groups. Kaplan-Meier and comparison
between both groups were made using Log-Rank test,
considering non-related death as censure. We per-
formed a crude estimation of the effect of treatment
on the evolution of eGFR by generalized estimating
equation (GEE) model using an AR(1) matrix to esti-
mate the intra-subject correlation. These models
included treatment effect, time of follow-up and their
interaction with treatment. GEE models of treatment
effect were adjusted for confounding factors including
infectious disease. As a useful clinical evaluation of
prediction values of change of eGFR (Δ of change)
from 6 months before to rejection, we proposed a cut-
off using the Likelihood Ratio (LR+) defined as ratio
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sensitivity/(1-specificity) from a ROC curve [22]. Esti-
mation of risk of graft loss at 24 months due to treat-
ment or a high delta of change of eGFR was
performed calculating odds ratios (OR) and their con-
fidence intervals at 95% (CI 95%) from logistic regres-
sion models. All statistical analyses were performed
using IBM SPSS statistics V20.0 software (IBM Corp,
Armonk, NY, USA). Two-sided P-values < 0.05 were
used to indicate statistical significance.
Results
Sixty-two patients with TG (cg ≥ 1) and diagnosis of
active c-aABMR according to Banff 2017 classification,
were retrospectively identified and included in the study.
Twenty-three received treatment with RTX, IVIG, and
PE, whereas 39 did not receive additional treatment and
were considered the control group. The median length
of follow-up was 27 months.
In all patients but one, the indication of graft biopsy
was in the context of deterioration of renal function or
proteinuria (> 1 g/day). In the remaining patient, the
biopsy was performed as follow-up biopsy after border-
line rejection.
Table 1 summarized the demographic and clinical
characteristics at the time of c-aABMR diagnosis. At the
time of c-aABMR diagnosis, treated patients were
significantly younger than those not treated 43.6 ± 13.2
vs. 53.6 ± 16.1 years (P = 0.008). However, CCI was not
different between groups. In the two groups, the
immunosuppressive regimens were similar (Table 1).
Type of donor and prior kidney transplants were not
statistically different between both groups (Table 1).
Mean donor age was lower in the treated group 43.05 ±
15.69 vs. 50.89 ± 11.99 years (P = 0.035).
Treatment
In all treated patients RTX was initiated between one
and 3 weeks after c-aABMR diagnosis. 82.6% of patients
treated with RTX received two doses with a mean cumu-
lative dose of 1008 ± 342 mg.
The mean number of PE sessions was 5.8 ± 0.38, and
mean total processed volume was 24.2 ± 5.4 L. The dose
of IVIG was 200 mg/kg, after every second PE.
In the control group, six patients presented concomi-
tant acute cellular rejection and were treated with
corticoids.
Graft survival censoring death was not different be-
tween both groups (Fig. 1), Log Rank P = 0.92. The pro-
portion of graft loss at 12 and 24 months after c-aABMR
diagnosis in treated and control groups was not statisti-
cally significant, 7 patients (30%) vs. 8 patients (34.7%)
and 8 (34.7%) vs.13 (33.3%) respectively.
Patient survival
Four patients died in the treated group, two of sepsis (10
and 45 months after the initiation of treatment) and two
of sudden death at home (3 and 64 months after
c-aABMR treatment). None of the patients in the
control group died.
Kidney function, proteinuria, and presence of DSA
The mean eGFR at diagnosis of c-aABMR and 6 months
before was not different between groups (Table 1 and
Fig. 2a). Also, proteinuria at diagnosis was similar in
both groups (Table 1).
The mean eGFR at 6, 12 and 24 months in treated and
control patients was not different (Fig. 2a). Even if we
split according to graft outcome eGFR follow-up was
similar between treated and control patient. (Figs 2b and
Additional file 1: Figure S1).
An elevated ΔeGFR (eGFR 6 months before diagno-
sis – eGFR at diagnosis of cABMR) was related to
graft loss during the first 24 months after diagnosis.
A proposed cut of 13 ml/min in ΔeGFR was obtained
from ROC analysis with LR+ = 3.34. A decrease of
eGRF of 13 ml/min or more was an independent
indicator of graft loss in the first 24 months with
OR = 5 (95% CI = 1.5–16.9; P = 0.01). The impact of
ΔeGFR was influenced neither in magnitude or statis-
tical significance in a multivariate approach, adjusted
by treatment (Table 2). Also proteinuria higher than
2.5 g/day (LR+ = 3.6), adjusted for treatment, was
associated with loss of graft at 24 months in both
groups (OR = 3; 95% CI = 1.22–7.37; P = 0.016).
We have evaluated the impact of treatment on the
deterioration of renal function in a longitudinal model
analysis (Fig. 3), showing that the impairment of eGFR is
independent of the treatment in a crude estimation
model. Also, we evaluated the impact of treatment
adjusted by possible confounding factors such as age,
Charlson’s index, graft loss, IFTA, microvascular inflam-
mation (MVI), transplant glomerulopathy (TG), glomer-
ulitis and peritubular capillaritis scores, proteinuria or
presence of infections. However, the decrease in eGFR
remains independent of the treatment (Fig. 3).
Proteinuria was not different in both groups at 6 and
12 months, mean 1.8 ± 1.2 vs. 1.7 ± 1.5 and 1.7 ± 1 vs.
1.8 ± 1.8 g/g (P = 0.9) creatinine respectively.
Anti-HLA antibodies were more prevalent in the
treated patients, but no difference was observed in de
novo DSA prevalence (P = 0.03 and 0.17 respectively).
Regarding the DSA class, 22% were class II, 33,3% class I
and, 44,4% class I and II.
The positivity of DSA and anti-HLA antibodies were
not associated with worse graft survival at 24 months in
our series (P = 0.06 and 0.65 respectively).
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Dialysis vintage (months) 32.6 ± 24.2 41.3 ± 38.7 0.37
Donor Age 43.05 ± 15.69 50.89 ± 11.99 0.008
Donor type (Living donor) 9 (39.1%) 12 (30.7%) 0.5
First kidney transplant 13 (56.5%) 27 (69.2%) 0.31
HLA mistmatch (A, B, DR) 3.27 ± 1.1 3.8 ± 1.5 0.12
Desensitization (PE + RTX) 1 (4.34%) 1 (2.56%) 0.7
Induction (Yes) 16 (69.56%) 30 (76.92%) 0.52
Thymoglobulin / ATG 10 (43.48%) 15 (38.46%) 0.7
Basiliximab 3 (13.04%) 13 (33.3%) 0.8
Other 3 (13.04%) 2 (5.12%) 0.3
IS at time of transplantation n (%)
Tacrolimus + MMF/MPA + PDN 12 (52.2%) 24 (58.9%)
Cyclosporine + MMF/MPA + PDN 3 (13.04%) 5 (12.82%)
Cyclosporine + PDN 5 (21.74%) 3 (7.69%)
mTORi + MMF/MPA + PDN 1 (4.35%) 5 (12.82%)
Tacrolimus + mTORi + PDN 1 (4.35%) 1 (2.56%)
Cyclosporine + mTORi + PDN 1 (2.56%)
Cyclosporine + Azathioprine + PDN 1 (4.35%)
Previous treated rejections of this allograft
Cellular rejection 6 (26.1%) 10 (25%) 0.97
Humoral rejection 7 (30.4%) 6 (15.38%) 0.26
At the time of c-aABMR diagnosis
Sex (Female/Male) 8/15 14/25 0.92
Age (years) 43.59 ± 13.2 53.6 ± 16.1 0.013
Charlson comorbidity index (CCI) 0.83 ± 1.1 0.97 ± 1.27 0.7
Time KT to active c-aABMR (months) 92.2 ± 75 93.3 ± 55.1 0.67
eGFR (mL/min) at c-aABMR diagnosis 30.9 ± 13.5 33.4 ± 11.6 0.45
eGFR (mL/min) 6 months before cABMR 40 ± 11 42.9 ± 10.2 0.3
Proteinuria (mg/g) at c-aABMR diagnosis 2286 ± 2248 1763 ± 1427 0.31
DSA (+) 6 /9 3 / 11 0.17
Anti-HLA Antibodies (+) 13 / 16 19 / 37 0.041
IS at time of c-aABMR diagnosis n (%)
PDN + other IS 17 (73.9%) 22 (55%)
Tacrolimus + MMF/MPA ± PDN 9 (39.1%) 17 (42.5%)
mTORi + MMF/MPA ± PDN 2 (8.69%) 7 (17.5%)
Cyclosporine + MMF/MPA ± PDN 4 (17.39%) 6 (15%)
Tacrolimus + PDN 3 (13.04%) 4 (10%)
MMF/MPA + PDN 1 (4.34%) 3 (7.5%)
Cyclosporine ± PDN 2 (8.69%) 2 (5%)
Tacrolimus + mTORi ± PDN 1 (4.34%) 1 (2.5%)
Cyclosporine + mTORi 1 (4.34%)
Results are shown as mean ± SD or absolute frequencies (%) for quantitative and qualitative variables respectively. GFR glomerular filtrate rate, KT kidney
transplant, IS immunossupression, mTORi mammalian target of rapamycin inhibitor, MMF/MPA mycophenolate mofetil or mycophenolic acid, cABMR chronic
antibody-mediated rejection; PDN, prednisone, RTX Rituximab
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Histological features
The time between renal transplantation and graft biopsy
was similar in treated and control patients, 92.2 ± 75 and
93.3 ± 55 months respectively (P = 0.94).
At diagnosis, histologically acute inflammatory and
chronic lesions related to c-aABMR and TG were similar
in both groups (Table 3). Transplant glomerulopathy
and IFTA were similar in treated and control patients,
1.74 ± 0.83 vs. 1.83 ± 0.77 (P = 0.54) and 1.61 ± 0.78 vs.
1.83 ± 0.84 (P = 0.27) respectively. The presence of IFTA
≥ two was associated with graft loss at 24 months,
(OR = 4.7; 1.19–18.5; P = 0.02).
C4d deposition was more frequent in treated patients
19 (82.6%) vs. 17 (43.6%) (P = 0.001). The positivity of
C4d, the severity of MVI (g + ptc) and TG degree were
not associated with graft loss or worse survival.
Ten of the 23 treated patients had post-treatment
follow-up biopsies within the first year after treatment
with persisting active c-aABMR in all ten biopsies.
Adverse events
Infections that required hospitalization at least 48 h
were more common in treated than non-treated patients
during the first year after c-aABMR diagnosis, 15 vs. 8
(OR = 4.22; 95% CI = 1.37–13.1; P = 0.012), this reflects a
ratio of infection/patient per year of 0.65 and 0.25 in
treated and control patients respectively.
Infections were respiratory (8), urinary tract (6), cuta-
neous and mucosal (3), abdominal (4), disseminated zos-
ter (1), and sepsis (1). The microbiological isolation was
negative in 12 cases, 3 Pseudomonas aeruginosa, 2
Cytomegalovirus, 1 Klebsiella pneumoniae, 1 Escherichia
coli, 1 Enterococcus faecalis, 1 Campylobacter jejuni and
1 Herpes Zoster virus.
A CCI of 3 was associated with more infectious com-
plications in the control group (OR = 8.7; 95% CI = 1.15–
65.9; P = 0.036), but not in the treated patients (P =
0.16). Related to adverse reactions in PE sessions or
RTX infusion, only one patient developed tetany related
to hypocalcemia.
Fig. 1 Renal allograft survival censoring death after c-aABMR diagnose.
Treatment: patients under rituximab-containing treatment (yes), control
patient group (no). Chronic active antibody-mediated
rejection (c-aABMR)
Fig. 2 Estimated glomerular filtrate rate (eGFR) follow-up before and
after c-aABMR diagnose. a eGFR evolution of treated and control
patient groups. b eGFR evolution according to graft outcome in
both groups. Chronic active antibody-mediated rejection (c-aABMR)
Table 2 Risk of graft loss at 24 months according to ΔeGFR
and treatment
OR & (95% CI) P value Model
Change in ΔeGFR > 13 ml/min 5 (1.5 – 16.9) 0.006 Univariate
Treatment 1.2 (0.4 - 3.5) 0.736 Univariate
Change in ΔeGFR > 13 ml/min 5 (1.5 – 16.9) 0.006 Multivariate
Treatment 1.1 (0.3 - 3.4) 0.897
ΔeGFR eGFR six months before diagnosis - eGFR at diagnosis of c-aABMR
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Discussion
In this study, treatment with rituximab + IVIG and PE
was not associated with improved graft survival when
compared with the control group. On the other hand,
the incidence of infections requiring hospitalization
within 1 year after treatment was more than doubled in
the treated group.
Chronic antibody-mediated damage is the main limita-
tion for long-term graft survival, but currently, only
scarce data are available about the treatment of active
c-aABMR with TG. In small retrospective series of cases,
the partial effectiveness of RTX and IVIG has been re-
ported [7–10]. Rostaing et al. reported 14 patients with
TG treated with RTX and steroids showing stabilization
or improvement of renal function in seven patients. Four
patients (28.5%) presented severe infections in the first
year after treatment [23].
A prospective study in 20 pediatric patients with
c-aABMR treated with one dose of RTX and a high dose
of IVIG reported good response in all the patients
Fig. 3 Crude and adjusted estimation of eGFR according to GEE longitudinal models. Crude model (a); adjusted by graft loss (b); adjusted by IFTA
(interstitial fibrosis and tubular atrophy) and MVI (microvascular inflammation) (c); adjusted by age and Charlson comorbidity index (d); adjusted
by proteinuria (e); adjusted by glomerulitis, capillaritis and transplant glomerulopathy (f); adjusted by infection disease complications in the
follow-up (g). Estimated glomerular filtrate rate (eGFR)
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without TG, but only in 45% of the patients with TG
[10]. The response was defined as a reduction in the
decline of GFR of 30%.
In another retrospective series of 31 patients with
c-aABMR and TG treated with RTX (n = 14) vs. no
treatment (n = 17), only eight patients responded to
treatment [24]. The response was defined as a decline or
stabilization of serum creatinine for at least 1 year.
These studies highlight the importance of TG as a
marker of chronic damage and a poor prognosis. On the
other hand, efficacy was based on graft function
stabilization, which is difficult to distinguish from the
natural history of the disease in the absence of an un-
treated control group. Indeed, in our control group,
some patients stabilized their renal function. As in other
reported series, the evolution of these patients is hetero-
geneous in both groups, which highlights the importance
of having a control group in future studies.
Other recent studies reported that RTX treatment did
not improve graft survival compared to an untreated
group. Moreover, a higher incidence of adverse effects
was detected in the treatment groups [11, 12]. How-
ever, the untreated groups were small in both studies,
and they did not evaluate the combination of RTX,
PE, and IVIG.
We performed the analysis using two comparable co-
horts. Also, c-aABMR treatment was homogeneous.
The decision to treat was based on individual clinical
judgment and seems to be influenced by the perception
of a better performance status of the patient, younger
age, younger donor and less risk of infections. However,
even with this potential positive selection bias, severe in-
fections were more frequent in treated patients than in
the older control group. In fact, the CCI was similar in
both groups but was only associated with more infec-
tions in the control patients.
On the contrary with results presented in other studies
[10], the severity of transplant glomerulopathy, (cg)
score, was not associated with worse survival or loss of
the graft at 24 months. Probably TG indicates a late
non-reversible manifestation of antibody-mediated pro-
cesses. Ten patients had a control biopsy after treatment,
none presented improvement of TG.
In contrast with our data Kahwaji et al. suggest that
patients with a high ptc and MVI scores may benefit
from treatment with IVIG and RTX. But this was a trend
that was not statistically significant [12]. Similar to our
findings the authors did not find C4d positivity to be as-
sociated with worse graft outcomes, which is in contrast
to the previous reports [5, 25–29].
A low eGFR at diagnosis is associated with graft loss
at 24 months [11, 12]. We postulate that ΔeGFR, be-
tween 6 months before rejection and the time of diagno-
sis of rejection, ≥13 ml/min is more helpful to identify
the patients with worse graft survival at 24 months.
In an observational study, 114 consecutive kidney
transplant patients with c-ABMR were treated with ste-
roids and IVIG. Three-fourths of patients lost their kid-
ney grafts with a median survival of 1.9 years. The
addition of rituximab or thymoglobulin in 40% of pa-
tients did not improve graft survival [30].
Recently a Spanish multicenter randomized trial has
been performed in order to analyze the efficacy of rituxi-
mab and IVIG vs. placebo in 24 patients with TG and
DSA positivity (12 placeboes vs. 12 treatments) [13]. The
primary outcome was the difference in the decline of
eGFR at 12 months. In concordance with our study,
there was no difference in eGFR decline. Unfortunately,
the study was stopped, after recruiting only 50% of the
minimal sample calculated, due to low inclusion rate,
and was underpowered, thus, highlighting the difficulty
for prospective studies in this area.
Another strategy includes the use of bortezomib, a
proteasome inhibitor. Recently a randomized trial has
been presented comparing bortezomib treatment vs. pla-
cebo in late ABMR, which included 28 patients with
cABMR. Bortezomib treatment failed to induce a rever-
sal in decline of eGFR, DSA changes or morphologic
and molecular features of disease activity in follow-up
biopsies. In this trial, treatment was associated with sub-
stantial toxicity [31].
Given the poor results and the higher incidence of
infectious complications, the unmet need is to improve
diagnosis and enhance treatment options. Use of elec-
tron microscopy to detect early forms of TG (cg = 1a) or






MVI (g+tc) 2.78 ± 1.35 2.87 ± 1.36 0.67
i 0.6 ± 0.78 0.56 ± 0.65 0.95
t 0.17 ± 0.49 0.25 ± 0.69 0.97
g 1.52 ± 0.94 1.4± 0.94 0.63
ptc 1.26 ± 0.86 1.4 ± 0.79 0.4
ah 1.43 ± 1.04 1.38 ± 1.1 0.91
cg 1.74 ± 0.83 1.83 ± 0.77 0.54
ci 1.52 ± 0.79 1.83 ± 0.88 0.17
ct 1.56 ± 0.73 1.67 ± 0.89 0.62
IFTA 1.61 ± 0.78 1.83 ± 0.84 0.27
cv 1.17 ± 0.83 1.39 ± 0.87 0.46
C4d deposition 19 (82.6%) 17 (43.6%) 0.01
acute cellular rejection 0 6 0.05
Results are shown as mean ± SD or absolute frequencies (%) for quantitative
and qualitative variables respectively. i interstitial inflammation, t tubulitis, g
glomerulitis, ptc peritubular capillaritis, ah arterial hyalinosis, cg transplant
glomerulopathy, ci interstitial fibrosis, ct tubular atrophy, IFTA interstitial
fibrosis + tubular atrophy, cv vascular fibrous intimal thickening
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increased expression of gene transcripts indicative of
endothelial injury might be helpful to improve graft
survival.
New therapeutic options with more potent and less
toxic immunosuppressive drugs or alternative immuno-
logical interventions are required. In this regard, two
small prospective studies evaluated the complement sys-
tem blockade at different levels in the treatment and
prevention of c-aABMR and TG, without changes in
long-term outcomes [32, 33].
In another recent report, Tocilizumab (Anti-IL6 recep-
tor monoclonal antibody) showed promising results with
stabilization of renal function in a small series of
patients with c-aABMR and TG [34].
A significant cause of DSA and c-aABMR develop-
ment is non-adherence to immunosuppression therapy.
In this context, it seems to be more efficient and less
dangerous to focus on promoting immunosuppressant
therapy adherence rather than treating c-aABMR with
TG aggressively.
This study presents a large group of patients with
uniform pathology and treatment. However, the retro-
spective nature of the study is a limitation. DSA, and
anti-HLA description is incomplete, hypogammaglo-
bulinemia was not recorded and the dose of IVIG
was low. In spite of the impossibility to assess the
presence of DSA in all patients, the failure to demon-
strate DSA does not rule out its existence [35]. The
Banff´17 classification recognizes the fact that current
DSA testing methods do not detect all antibodies that
are potentially injurious to the allograft, and recom-
mends the use of alternative markers that are not
available in our center [3]. Recently, Sablik et al. ana-
lyzed whether cases suspicious for c-aABMR (DSA
negative, n = 24) differ from cases of c-aABMR (DSA
positive, n = 17) with respect to renal histology, allo-
graft function and long-term graft survival [36]. There
were no statistically significant differences on the de-
cline of allograft function and renal allograft survival
in cases with or without DSAs.
On the other hand, a strength of this study is that it
shows a realistic incidence of serious infectious compli-
cations after treatment that should be taken into account
in the therapeutic decision.
Conclusions
In summary, the rapid decline in GFR between 6 months
before rejection diagnosis and the time of diagnosis is
associated with poor prognosis. Treatment with RTX,
PE, and IVIG in patients with active c-aABMR with TG
was not associated with better graft survival, but a sig-
nificant increase in serious infectious complications was
observed.
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Additional file 1: Figure S1. Individual eGFR follow-up. (a-b) eGFR
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evolution of control and treated patients with graft loss. eGFR, estimated
glomerular filtrate rate; c-aABMR, chronic active antibody-mediated
rejection (DOCX 444 kb)
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